Advanced Biomed Inc. (ADVB) Cash Flow Statement
Where ADVB’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$62,735
- Capital expenditures
- $5 0.1% of revenue
- Free cash flow
- −$961,341 −23,378.9% margin
- Returned to shareholders
- —
- Change in cash
- −$2.5M cash at year-end $385,535
Drawn to scale: where the cash came from and how it was used. Hover for values.
ADVB operating cash flow, capex and free cash flow
ADVB cash flow trends, FY2021–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$473,975FY2021 | −$62,735FY2026 | — | |
| Capital expenditures | $25,442FY2021 | $5FY2026 | −81.9%/yr | |
| Free cash flow | −$499,417FY2021 | −$961,341FY2026 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ADVB cash flow by activity
ADVB net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ADVB cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | $6.7M | −$101,524 | −$2.8M | −$3.7M | −$4.0M | −$1.8M |
| Depreciation & amortization | — | $10,711 | $399,602 | $365,231 | $126,632 | $57,850 |
| Stock-based compensation | $1.7M | — | — | — | — | — |
| Change in working capital | $4,776 | −$90,650 | $256,336 | $253,714 | $1.5M | $1.3M |
| Other non-cash items | −$8.5M | −$1 | $0 | $150,207 | $1.7M | $0 |
| Cash from operating activities | −$62,735 | −$181,464 | −$2.1M | −$3.0M | −$741,450 | −$473,975 |
| Investing activities | ||||||
| Capital expenditures | −$5 | −$985 | −$74,110 | −$212,523 | −$1.3M | −$25,442 |
| Investments (net) | — | — | −$74,110 | −$263,009 | −$1.1M | −$25,442 |
| Acquisitions & other investing | −$80,748 | $0 | $74,110 | $212,523 | $1.3M | $25,442 |
| Cash from investing activities | −$80,753 | −$985 | −$74,110 | −$263,009 | −$1.1M | −$25,442 |
| Financing activities | ||||||
| Net borrowing (repayment) | — | — | $1.7M | $0 | — | — |
| Shares issued | $0 | $0 | $0 | $1.0M | $6.1M | $697,164 |
| Other financing | $63,413 | $184,867 | $209,500 | −$553,471 | $0 | $0 |
| Cash from financing activities | $63,413 | $184,867 | $1.9M | $458,137 | $6.1M | $697,164 |
| Summary | ||||||
| Net change in cash | −$2.5M | $19,018 | −$14,306 | −$2.2M | $4.7M | $217 |
| Cash at end of period | $385,535 | $99,408 | $2.6M | $2.6M | $4.8M | $65,922 |
| Free cash flow | −$961,341 | −$182,450 | −$2.2M | −$3.2M | −$2.1M | −$499,417 |
| Free cash flow margin | −23,378.9% | — | — | — | — | — |
| Capex / revenue | 0.1% | — | — | — | — | — |
| Operating cash flow / net income | −0.01 | — | — | — | — | — |
| Sep '26 | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$395,900 | −$15,455 | $225,595 | −$386,901 | −$42,075 | −$907,904 | −$265,580 | −$809,386 | −$1.1M | −$145,345 | −$771,316 | −$1.7M |
| Depreciation & amortization | — | $9,326 | $466 | $47,992 | $2,375 | −$56,760 | $102,218 | $153,911 | $83,016 | $73,366 | $89,309 | $166,986 |
| Change in working capital | −$13,345 | $7,376 | $19,731 | −$271,494 | −$64,025 | −$88,709 | $133,682 | $179,647 | −$92,443 | $106,263 | $62,869 | $1.5M |
| Other non-cash items | $390,765 | −$8,142 | −$261,603 | $61 | −$3.3M | $211,532 | $0 | $0 | $0 | $0 | $0 | $150,207 |
| Cash from operating activities | −$18,480 | −$6,895 | −$15,811 | −$610,342 | −$3.4M | −$841,841 | −$29,680 | −$475,828 | −$1.1M | $34,284 | −$619,138 | $174,120 |
| Investing activities | ||||||||||||
| Capital expenditures | −$500 | −$35 | −$419 | −$1,771 | −$2,215 | $0 | −$19,978 | −$53,256 | −$26,699 | −$47,553 | −$2 | −$210,883 |
| Investments (net) | — | — | — | −$1,771 | −$2,215 | $10,692 | −$19,978 | −$53,256 | $26,699 | −$47,553 | $0 | −$200,641 |
| Acquisitions & other investing | −$78,268 | $4 | $6 | $1,771 | $2,215 | — | $19,978 | $53,256 | $26,699 | $47,553 | — | $210,883 |
| Cash from investing activities | −$78,768 | −$31 | −$413 | −$1,771 | −$2,215 | — | −$19,978 | −$53,256 | $26,699 | −$47,553 | — | −$200,641 |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $11,608 |
| Other financing | $29,654 | $8,015 | $9,625 | $447,462 | $5.9M | $78,327 | $392,525 | $323,536 | $562,199 | $667,879 | $313,206 | −$553,471 |
| Cash from financing activities | $29,654 | $8,015 | $9,625 | $447,462 | $5.9M | $78,327 | $392,525 | $323,536 | $562,199 | $667,879 | $313,206 | −$541,863 |
| Summary | ||||||||||||
| Net change in cash | −$69,308 | −$1,487 | −$4,264 | −$247,396 | $2.5M | $10,243 | $39,019 | −$55,731 | −$112,918 | $189,404 | −$35,061 | $92,781 |
| Cash at end of period | $12,102 | $81,410 | $82,897 | $2.7M | $5.2M | $2.6M | $2.6M | $2.6M | $2.7M | $2.8M | $2.6M | $2.6M |
| Free cash flow | −$17,980 | −$6,930 | −$16,230 | −$612,113 | −$3.4M | −$831,149 | −$49,658 | −$529,084 | −$1.0M | −$13,269 | −$619,138 | −$36,763 |
| Free cash flow margin | −445.4% | — | — | −3,558.8% | — | — | — | — | — | — | — | — |
| Capex / revenue | 12.4% | — | — | 10.3% | — | — | — | — | — | — | — | — |
| Operating cash flow / net income | — | — | −0.07 | — | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ADVB cash generation
In fiscal 2026 (ended June 30, 2026), Advanced Biomed generated -$0.1 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$1.0 million, −23,378.9% of revenue. Cash and equivalents fell by $2.5 million over the year.
Related: ADVB income statement, ADVB balance sheet. See the ADVB stock overview for the latest quote and news.
ADVB cash flow FAQ
What is Advanced Biomed's free cash flow?
Advanced Biomed's free cash flow was -$1.0 million in fiscal 2026: -$0.1 million of operating cash flow minus $0.0 million of capital expenditures It was -$0.2 million a year earlier..
How much cash does Advanced Biomed generate from operations?
Advanced Biomed generated -$0.1 million of cash from operating activities in fiscal 2026, −0.01 times its net income of $6.7 million.
How much does Advanced Biomed spend on capital expenditures?
Advanced Biomed spent $0.0 million on capital expenditures in fiscal 2026, 0.1% of revenue, compared with $0.0 million the year before.